Ginkgo Bioworks Holdings Inc DNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
-
The $59B Quiet Shift Reshaping How Patients Access Care
-
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
-
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
-
Ginkgo Bioworks Shares Rise After 4-Year, $47 Million Contract
Trading Information
- Previous Close Price
- $9.00
- Day Range
- $8.22–9.00
- 52-Week Range
- $5.37–17.58
- Bid/Ask
- $8.25 / $8.38
- Shares Outstanding
- 65.32M
- Market Cap
- $541.54M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 485
- Website
- https://www.ginkgobioworks.com
Valuation
|
Metric
|
DNA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.25 |
Price/Sales | 3.62 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DNA
|
|---|---|
Quick Ratio | 4.95 |
Current Ratio | 5.15 |
Interest Coverage | — |
Quick Ratio
DNA
Profitability
|
Metric
|
DNA
|
|---|---|
Return on Assets (Normalized) | −16.73% |
Return on Equity (Normalized) | −35.41% |
Return on Invested Capital (Normalized) | −22.04% |
Return on Assets
DNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%<Rd@h | LOCK|f?Jd@ | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|nZL>$w> | LOCK|xQ<P | $70B | |||
| argenx SE ADR
ARGX
| LOCK|MC?M?m | LOCK|>Vy | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|ywDx@b | LOCK|#<@? | $37B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&LqYnv | LOCK|&?w | $37B | |||
| Moderna Inc
MRNA
| LOCK|&K$!Qy> | LOCK|v^ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?<hYzj@ | LOCK|%#$gp | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>M@sYB | LOCK|>^ | $23B | |||
| Incyte Corp
INCY
| LOCK|ZJBm?H | LOCK|vG | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Yq?!MH | LOCK|R&% | $16B |
United States